OA12229A - Hydrochloride salts of 5-Ä4-Ä2-(N-methyl-N-(2-pyridy))amino)ethoxyÜbenzylÜthiazolidine-2.4-dione. - Google Patents

Hydrochloride salts of 5-Ä4-Ä2-(N-methyl-N-(2-pyridy))amino)ethoxyÜbenzylÜthiazolidine-2.4-dione. Download PDF

Info

Publication number: OA12229A
Authority: OA; OAPI
Prior art keywords: hydrochloride; methyl; compound; dione; amino
Prior art date: 2000-03-14

Application number

OA1200200285A

Other languages

English (en)

Inventor

Andrew Simon Craig

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-14

Filing date

2001-03-14

Publication date

2003-11-07

2001-03-14 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

2003-11-07 Publication of OA12229A publication Critical patent/OA12229A/en

Links

150000003840 hydrochlorides Chemical class 0.000 title abstract description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 32
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical class C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims abstract description 9
238000000034 method Methods 0.000 claims abstract description 7
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 46
238000000634 powder X-ray diffraction Methods 0.000 claims description 11
238000011282 treatment Methods 0.000 claims description 8
229910000041 hydrogen chloride Inorganic materials 0.000 claims description 6
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 6
238000001237 Raman spectrum Methods 0.000 claims description 5
238000002329 infrared spectrum Methods 0.000 claims description 5
239000002904 solvent Substances 0.000 claims description 4
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims description 2
239000003814 drug Substances 0.000 abstract description 2
239000000243 solution Substances 0.000 description 16
239000000203 mixture Substances 0.000 description 13
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
-1 acetone Chemical class 0.000 description 7
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
238000011321 prophylaxis Methods 0.000 description 5
239000000725 suspension Substances 0.000 description 5
238000001816 cooling Methods 0.000 description 4
239000000047 product Substances 0.000 description 4
239000007787 solid Substances 0.000 description 4
230000004584 weight gain Effects 0.000 description 4
235000019786 weight gain Nutrition 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
102000004877 Insulin Human genes 0.000 description 3
108090001061 Insulin Proteins 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
238000002425 crystallisation Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
239000000945 filler Substances 0.000 description 3
229940125396 insulin Drugs 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
239000000080 wetting agent Substances 0.000 description 3
XRSCTTPDKURIIJ-UHFFFAOYSA-N 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione;hydrochloride Chemical compound Cl.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O XRSCTTPDKURIIJ-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000007810 chemical reaction solvent Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
229960000443 hydrochloric acid Drugs 0.000 description 2
235000011167 hydrochloric acid Nutrition 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
238000011084 recovery Methods 0.000 description 2
239000012265 solid product Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000003826 tablet Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000000103 Anorexia Nervosa Diseases 0.000 description 1
208000032841 Bulimia Diseases 0.000 description 1
206010006550 Bulimia nervosa Diseases 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
208000007342 Diabetic Nephropathies Diseases 0.000 description 1
239000004150 EU approved colour Substances 0.000 description 1
208000030814 Eating disease Diseases 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
208000019454 Feeding and Eating disease Diseases 0.000 description 1
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
206010060378 Hyperinsulinaemia Diseases 0.000 description 1
206010020710 Hyperphagia Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
238000001069 Raman spectroscopy Methods 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
229940123464 Thiazolidinedione Drugs 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
238000011161 development Methods 0.000 description 1
208000033679 diabetic kidney disease Diseases 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
235000014632 disordered eating Nutrition 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000009509 drug development Methods 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
230000005284 excitation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
206010061989 glomerulosclerosis Diseases 0.000 description 1
239000008187 granular material Substances 0.000 description 1
150000008282 halocarbons Chemical class 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
230000000055 hyoplipidemic effect Effects 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000035879 hyperinsulinaemia Effects 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
201000009925 nephrosclerosis Diseases 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
235000020830 overeating Nutrition 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960004063 propylene glycol Drugs 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000007789 sealing Methods 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000012258 stirred mixture Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000759 toxicological effect Toxicity 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Diabetes (AREA)
Obesity (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

OA1200200285A 2000-03-14 2001-03-14 Hydrochloride salts of 5-Ä4-Ä2-(N-methyl-N-(2-pyridy))amino)ethoxyÜbenzylÜthiazolidine-2.4-dione. OA12229A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0006133.3A GB0006133D0 (en)	2000-03-14	2000-03-14	Novel pharmaceutical

Publications (1)

Publication Number	Publication Date
OA12229A true OA12229A (en)	2003-11-07

Family

ID=9887600

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200200285A OA12229A (en)	2000-03-14	2001-03-14	Hydrochloride salts of 5-Ä4-Ä2-(N-methyl-N-(2-pyridy))amino)ethoxyÜbenzylÜthiazolidine-2.4-dione.

Country Status (30)

Country	Link
US (2)	US7074811B2 (de)
EP (1)	EP1265893B1 (de)
JP (1)	JP2003527393A (de)
KR (1)	KR100746813B1 (de)
CN (1)	CN100516062C (de)
AP (1)	AP1545A (de)
AT (1)	ATE302202T1 (de)
AU (1)	AU777987B2 (de)
BG (1)	BG65924B1 (de)
BR (1)	BR0108870A (de)
CA (1)	CA2403109A1 (de)
CZ (1)	CZ20023074A3 (de)
DE (1)	DE60112729T2 (de)
DK (1)	DK1265893T3 (de)
DZ (1)	DZ3316A1 (de)
EA (1)	EA005115B1 (de)
ES (1)	ES2243458T3 (de)
GB (1)	GB0006133D0 (de)
HU (1)	HUP0300158A3 (de)
IL (2)	IL151425A0 (de)
MA (1)	MA25658A1 (de)
MX (1)	MXPA02008972A (de)
NO (1)	NO323448B1 (de)
NZ (1)	NZ520910A (de)
OA (1)	OA12229A (de)
PL (1)	PL357283A1 (de)
SK (1)	SK286399B6 (de)
UA (1)	UA73974C2 (de)
WO (1)	WO2001068646A1 (de)
ZA (1)	ZA200207292B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0021865D0 (en) *	2000-09-06	2000-10-18	Smithkline Beecham Plc	Novel pharmaceutical
GB0023971D0 (en) *	2000-09-29	2000-11-15	Smithkline Beecham Plc	Novel pharmaceutical
ES2278977T3 (es) *	2001-11-21	2007-08-16	Smithkline Beecham Plc	Bencenosulfonato de 5-(4-(2-(n-metil-n-(2-piridil)amino)etoxi)bencil)tiazolidin-2,4-diona; procedimiento para su preparacion; polimorfos i, ii y iii de los mismos; y su uso como ingrediente activo farmaceutico.
WO2003050112A1 (en) *	2001-12-13	2003-06-19	Smithkline Beecham Plc	Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129876D0 (en) *	2001-12-13	2002-02-06	Smithkline Beecham Plc	Novel pharmaceutical
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en)	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
WO2006018853A2 (en)	2004-08-19	2006-02-23	Hetero Drugs Limited	Novel polymorphs of efavirenz
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) *	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (de)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	Zusammensetzungen von DPP-IV-Inhibitoren
CN109503584A (zh)	2006-05-04	2019-03-22	勃林格殷格翰国际有限公司	多晶型
PE20110235A1 (es)	2006-05-04	2011-04-14	Boehringer Ingelheim Int	Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US20090076093A1 (en) *	2007-09-14	2009-03-19	Protia, Llc	Deuterium-enriched rosiglitazone
PE20140960A1 (es)	2008-04-03	2014-08-15	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
KR20190016601A (ko)	2008-08-06	2019-02-18	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
WO2010029089A2 (en)	2008-09-10	2010-03-18	Boehringer Ingelheim International Gmbh	Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US20100158821A1 (en) *	2008-12-22	2010-06-24	Eastman Chemical Company	Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products
EP2382216A1 (de)	2008-12-23	2011-11-02	Boehringer Ingelheim International GmbH	Salzformen einer organischen verbindung
TW201036975A (en)	2009-01-07	2010-10-16	Boehringer Ingelheim Int	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
US8106111B2 (en) *	2009-05-15	2012-01-31	Eastman Chemical Company	Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
NZ599298A (en)	2009-11-27	2014-11-28	Boehringer Ingelheim Int	Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
KR101927068B1 (ko)	2010-05-05	2018-12-10	베링거 인겔하임 인터내셔날 게엠베하	체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
CN106975074A (zh)	2010-06-24	2017-07-25	勃林格殷格翰国际有限公司	糖尿病治疗
US9034883B2 (en)	2010-11-15	2015-05-19	Boehringer Ingelheim International Gmbh	Vasoprotective and cardioprotective antidiabetic therapy
ES2713566T3 (es)	2011-07-15	2019-05-22	Boehringer Ingelheim Int	Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
EP3685839A1 (de)	2012-05-14	2020-07-29	Boehringer Ingelheim International GmbH	Linagliptin zur verwendung in der behandlung von albuminuria und nierenbedingten erkrankungen
EP4151218A1 (de)	2012-05-14	2023-03-22	Boehringer Ingelheim International GmbH	Linagliptin, ein xanthinderivat als dpp-4-inhibitor zur verwendung bei der behandlung von sirs und/oder sepsis
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en)	2014-02-28	2016-12-27	Boehringer Ingelheim International Gmbh	Medical use of a DPP-4 inhibitor
EP4233840A3 (de)	2016-06-10	2023-10-18	Boehringer Ingelheim International GmbH	Kombinationen aus linagliptin und metformin

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US137940A (en) *		1873-04-15		Improvement in elevators
US120078A (en) *		1871-10-17		Improvement in revolving flower-stands
US6288095B1 (en) *	1987-09-04	2001-09-11	Beecham Group P.L.C.	Compounds
EP0842925A1 (de) *	1987-09-04	1998-05-20	Beecham Group Plc	Substituierte Thiazolidindionderivate
GB9413975D0 (en) *	1994-07-11	1994-08-31	Fujisawa Pharmaceutical Co	New heterobicyclic derivatives
GB9124513D0 (en) *	1991-11-19	1992-01-08	Smithkline Beecham Plc	Novel process
US5741803A (en) *	1992-09-05	1998-04-21	Smithkline Beecham Plc	Substituted thiazolidinedionle derivatives
GB9218830D0 (en) *	1992-09-05	1992-10-21	Smithkline Beecham Plc	Novel compounds
US5708012A (en) *	1995-04-28	1998-01-13	Sankyo Company, Limited	Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
KR20060105005A (ko)	1997-06-18	2006-10-09	스미스클라인비이참피이엘시이	티아졸리딘디온 및 메트포르민을 사용한 당뇨병의 치료
US6664278B2 (en) *	1997-12-16	2003-12-16	Smithkline Beecham P.L.C.	Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
US20020137940A1 (en) *	1997-12-16	2002-09-26	Smithkline Beecham P.L.C.	5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
GB9909075D0 (en)	1999-04-20	1999-06-16	Smithkline Beecham Plc	Novel pharmaceutical
GB9909041D0 (en)	1999-04-20	1999-06-16	Smithkline Beecham Plc	Novel pharmaceutical
AU4307200A (en)	1999-04-23	2000-11-10	Smithkline Beecham Plc	Novel pharmaceutical
WO2000064896A1 (en)	1999-04-23	2000-11-02	Smithkline Beecham Plc	Polymorph of 5-[4-[2- (n-methyl-n-( 2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2,4-dione, maleic acid salt
PE20010040A1 (es)	1999-04-23	2001-03-10	Smithkline Beecham Plc	Polimorfo de sal del acido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-tiazolidina-2,4-diona
HU225919B1 (en)	1999-12-18	2007-12-28	Richter Gedeon Nyrt	Thiazolidine-derivatives, process for their preparation pharmaceutical and intermediates
CN1277965A (zh)	2000-06-14	2000-12-27	中国医药研究开发中心	盐酸罗格列酮及其应用
GB0021865D0 (en)	2000-09-06	2000-10-18	Smithkline Beecham Plc	Novel pharmaceutical

2000
- 2000-03-14 GB GBGB0006133.3A patent/GB0006133D0/en not_active Ceased
2001
- 2001-03-14 EA EA200200975A patent/EA005115B1/ru not_active IP Right Cessation
- 2001-03-14 JP JP2001567737A patent/JP2003527393A/ja active Pending
- 2001-03-14 WO PCT/GB2001/001131 patent/WO2001068646A1/en not_active Ceased
- 2001-03-14 MX MXPA02008972A patent/MXPA02008972A/es active IP Right Grant
- 2001-03-14 US US10/221,686 patent/US7074811B2/en not_active Expired - Fee Related
- 2001-03-14 AT AT01911921T patent/ATE302202T1/de active
- 2001-03-14 OA OA1200200285A patent/OA12229A/en unknown
- 2001-03-14 HU HU0300158A patent/HUP0300158A3/hu unknown
- 2001-03-14 NZ NZ520910A patent/NZ520910A/en not_active IP Right Cessation
- 2001-03-14 EP EP01911921A patent/EP1265893B1/de not_active Expired - Lifetime
- 2001-03-14 DK DK01911921T patent/DK1265893T3/da active
- 2001-03-14 UA UA2002097390A patent/UA73974C2/uk unknown
- 2001-03-14 IL IL15142501A patent/IL151425A0/xx unknown
- 2001-03-14 CA CA002403109A patent/CA2403109A1/en not_active Abandoned
- 2001-03-14 SK SK1330-2002A patent/SK286399B6/sk not_active IP Right Cessation
- 2001-03-14 DE DE60112729T patent/DE60112729T2/de not_active Expired - Lifetime
- 2001-03-14 CN CNB018000010A patent/CN100516062C/zh not_active Expired - Fee Related
- 2001-03-14 ES ES01911921T patent/ES2243458T3/es not_active Expired - Lifetime
- 2001-03-14 CZ CZ20023074A patent/CZ20023074A3/cs unknown
- 2001-03-14 DZ DZ013316A patent/DZ3316A1/de active
- 2001-03-14 PL PL01357283A patent/PL357283A1/xx not_active Application Discontinuation
- 2001-03-14 KR KR1020027011997A patent/KR100746813B1/ko not_active Expired - Fee Related
- 2001-03-14 BR BR0108870-0A patent/BR0108870A/pt not_active IP Right Cessation
- 2001-03-14 AP APAP/P/2002/002600A patent/AP1545A/en active
- 2001-03-14 AU AU40843/01A patent/AU777987B2/en not_active Ceased
2002
- 2002-08-20 BG BG107012A patent/BG65924B1/bg unknown
- 2002-08-22 IL IL151425A patent/IL151425A/en not_active IP Right Cessation
- 2002-09-09 NO NO20024307A patent/NO323448B1/no not_active IP Right Cessation
- 2002-09-11 ZA ZA200207292A patent/ZA200207292B/en unknown
- 2002-09-12 MA MA26814A patent/MA25658A1/fr unknown
2005
- 2005-07-18 US US11/183,353 patent/US20050267162A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU4084301A (en)	2001-09-24
IL151425A0 (en)	2003-04-10
DK1265893T3 (da)	2005-11-14
BR0108870A (pt)	2002-12-17
DE60112729T2 (de)	2006-06-08
EA005115B1 (ru)	2004-10-28
SK286399B6 (sk)	2008-09-05
CA2403109A1 (en)	2001-09-20
NZ520910A (en)	2004-06-25
HUP0300158A2 (en)	2003-05-28
EA200200975A1 (ru)	2003-02-27
MXPA02008972A (es)	2003-02-10
BG65924B1 (bg)	2010-05-31
US20050267162A1 (en)	2005-12-01
ATE302202T1 (de)	2005-09-15
DZ3316A1 (de)	2001-09-20
IL151425A (en)	2009-08-03
UA73974C2 (en)	2005-10-17
AU777987B2 (en)	2004-11-11
DE60112729D1 (de)	2005-09-22
HUP0300158A3 (en)	2005-04-28
CN1358184A (zh)	2002-07-10
KR100746813B1 (ko)	2007-08-06
SK13302002A3 (sk)	2003-02-04
GB0006133D0 (en)	2000-05-03
HK1052502A1 (en)	2003-09-19
CN100516062C (zh)	2009-07-22
ZA200207292B (en)	2003-05-06
EP1265893B1 (de)	2005-08-17
US20040152901A1 (en)	2004-08-05
JP2003527393A (ja)	2003-09-16
CZ20023074A3 (cs)	2003-02-12
AP1545A (en)	2006-01-12
US7074811B2 (en)	2006-07-11
NO20024307L (no)	2002-09-09
EP1265893A1 (de)	2002-12-18
PL357283A1 (en)	2004-07-26
KR20020079998A (ko)	2002-10-21
WO2001068646A1 (en)	2001-09-20
AP2002002600A0 (en)	2002-09-30
MA25658A1 (fr)	2002-12-31
NO323448B1 (no)	2007-05-07
NO20024307D0 (no)	2002-09-09
ES2243458T3 (es)	2005-12-01
BG107012A (bg)	2003-04-30

Publication	Publication Date	Title
OA12229A (en)	2003-11-07	Hydrochloride salts of 5-Ä4-Ä2-(N-methyl-N-(2-pyridy))amino)ethoxyÜbenzylÜthiazolidine-2.4-dione.
US20070191435A1 (en)	2007-08-16	Hydrochloride salt of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
US7291740B2 (en)	2007-11-06	5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione Mesylate salt
EP1173437A2 (de)	2002-01-23	Thiazolidindionderivat und seine verwendung als antidiabetikum
US20040048899A1 (en)	2004-03-11	Tartrate salts of thiazollidnedione derivative
AU2001284284A1 (en)	2002-06-13	The hydrochloride salt of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione
US20040014790A1 (en)	2004-01-22	Tartrate salt of thiazolidinedione derivative
US20040029926A1 (en)	2004-02-12	Thiazolidinone nitrate salt
HK1052502B (en)	2006-03-31	Hydrochloride salts of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
US20040087629A1 (en)	2004-05-06	Tartrate salts of thiazolidinedione derivative
US20040102485A1 (en)	2004-05-27	Tartrate salt of thiazolidinedione derivative
CA2423978A1 (en)	2002-04-04	Potassium salt of thiazolidinedione and its use as antidiabetic
HK1057749B (en)	2006-03-10	The hydrochloride salt of 5[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione